• Publications
  • Influence
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
BACKGROUND Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy in reducing the risk of death among men with metastatic castration-resistant prostate cancer. Expand
  • 4,065
  • 157
  • PDF
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
PURPOSE To update eligibility and outcome measures in trials that evaluate systemic treatment for patients with progressive prostate cancer and castrate levels of testosterone. METHODS A committeeExpand
  • 1,720
  • 84
  • PDF
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
BACKGROUND Androgen-deprivation therapy (ADT) has been the backbone of treatment for metastatic prostate cancer since the 1940s. We assessed whether concomitant treatment with ADT plus docetaxelExpand
  • 1,268
  • 73
  • PDF
Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
Purpose: Immune dysfunction reported in renal cell carcinoma (RCC) patients may contribute to tumor progression. Myeloid-derived suppressor cells (MDSC) represent one mechanism by which tumors induceExpand
  • 718
  • 41
  • PDF
Treatment of Non‐Metastatic Muscle‐Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline
Purpose: This multidisciplinary, evidence‐based guideline for clinically non‐metastatic muscle‐invasive bladder cancer focuses on the evaluation, treatment and surveillance of muscle‐invasive bladderExpand
  • 247
  • 19
  • PDF
Zoledronic acid reduces skeletal‐related events in patients with osteolytic metastases
This study evaluated the dose–response relation for zoledronic acid, a new generation high potency bisphosphonate, given as a 5‐minute infusion in patients with malignant osteolytic disease.
  • 494
  • 14
Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial.
LBA2 Background: Docetaxel (D) improves OS of men with mPrCa who have progressed on androgen deprivation therapy (ADT). We aimed to assess the benefit of upfront chemohormonal therapy for metastaticExpand
  • 169
  • 12
Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
Sunitinib is an inhibitor of the vascular endothelial growth factor and platelet-derived growth factor receptors, and it has antitumor activity in metastatic renal cell carcinoma and gastrointestinalExpand
  • 360
  • 10
  • PDF
Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients
Purpose: Immune dysfunction is well documented in renal cell carcinoma (RCC) patients and likely contributes to tumor evasion. This dysfunction includes a shift from a type-1 to a type-2 T-cellExpand
  • 409
  • 10
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.
Purpose Docetaxel added to androgen-deprivation therapy (ADT) significantly increases the longevity of some patients with metastatic hormone-sensitive prostate cancer. Herein, we present the outcomesExpand
  • 184
  • 7
  • PDF